Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Biogen (BIIB) PT Raised to $377 at BMO Capital Following 'Deep Dive on Aducanumab, More Confident on Phase 3 Outcome'
September 13, 2017 9:48 AM EDTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $377.00 (from $328.00) while maintaining a Market Perform rating, following a review of aducanumab.
Analyst M. Ian Somaiya notes a positive outlook follow a detailed review of aducanumab, suggesting the analysis points to... More
